onkommon.com
Programme R7
Liquid Biopsy & Residual Disease Analytics
What monitoring interval actually changes management?
Coming soon
The problem
Residual-disease monitoring is being sold before the questions that make it useful have been answered, chiefly, how often to test and what to do with the result.
In India it is largely reserved for patients who can pay, which makes the interval question an equity question as well as a scientific one.
The questions
- How low can a circulating tumour DNA signal be pushed before it stops being real?
- What monitoring interval actually changes management, rather than simply generating anxiety?
- Can residual-disease detection be made affordable enough for routine Indian use?
What we are contributing
Our monitoring and survivorship subscriptions are only defensible if somebody has shown the intervals are right. We are choosing to be the people who show it, including if the answer is that a longer interval is sufficient.
That is a commercially inconvenient question to ask about your own recurring product, which is precisely why it belongs in a research wing funded separately from the clinic.
How the work is done
- Signal processing on low-frequency variant data
- Error-model development
- Longitudinal trajectory modelling
- Lead-time and clinical-utility analysis, linked to health-economic modelling in R10
What it runs on
- Serial consented samples via OnKommon
- Matched imaging and clinical outcomes
- Public benchmark datasets
What it produces
- Monitoring-interval evidence
- Residual-disease analytic methods
- Clinical-utility studies
- Publications
Why it is not just science
How this changes care here
- Sets the intervals used in our own surveillance programmes
- Determines who is genuinely a monitoring candidate
Funding fit
Diagnostic industry collaboration; national biomedical grants.
What we are looking for
- Diagnostic partners for assay development
- Health-economics collaborators
- Funding for serial sample collection
Deliberately empty
Publications, funding and results
Nothing appears in this section until it exists in writing. No paper in preparation, no grant under review, no result not yet published. That rule applies with particular force to a research page.